Fosrenol: profile and news

Shire plc: Strong 2005 Performance Supports Positive Outlook Feb 23, 2006
...filed with the FDA and the European Medicines Agency (EMEA); - XAGRID for Thrombocythemia, roll-out commenced in Europe; - FOSRENOL for Hyperphosphatemia ... - PR Newswire (press release),

Shire Plc: Strong 2005 Performance Supports Positive Outlook Feb 23, 2006
Pharmaceuticals Inc. (New River); - FOSRENOL higher strengths (750mg and 1000mg) launched in the US. 2005 Business Development. - Sale ... - International News Service,

Shire: Shire 2006 Outlook Feb 24, 2006
Full European launch of this product is now expected H1 2007; - Continuing the launch of FOSRENOL higher strengths in the US. The ... - Webbolt Business News (subscription),

Shire annual underlying earnings fall Feb 23, 2006
AFX) - British drug developer Shire PLC reported a 5 pct fall in underlying annual earnings, dented by the cost of launching two new drugs, Fosrenol for renal ... - Forbes

Shire targets double digit growth Feb 23, 2006
The group said it would also increase its marketing spend as it looks to roll-out Fosrenol across Europe and maximize Adderall XR's market share. ... - ShareCast,

Award for scientist's platinum work - 22nd February 2006 Feb 22, 2006
Development led by Dr Abrams on drugs based on platinum gave rise to NX473 and Fosrenol, as well as promising future stem cell products and HIV inhibitors. ... - Platinum today,

/FIRST AND FINAL ADD -- LNTH005 -- Shire plc: Strong 2005 ... Feb 23, 2006
30,558 +45% 10% _____ _____ _____ _____ GP AGRYLIN/XAGRID NORTH AMERICA 4,031 22,259 -82% 1% ROW 10,381 8,276 +25% 2% FOSRENOL 29,032 - N/A ... - PR Newswire (press release),

AnorMED's CEO Michael Abrams receives prestigious Julia Levy Award ... Feb 21, 2006
Dr. Abrams in recognition of his critical involvement in the development of platinum-based cancer chemotherapeutic drugs leading to NX473; and FOSRENOL(TM), a ... - Canada NewsWire (press release),

Shire: Shire plc : Strong 2005 Performance Supports Positive ... Feb 24, 2006
NRP104 for ADHD filed with the FDA by New River Pharmaceuticals Inc. (New River); - FOSRENOL higher strengths (750mg and 1000mg) launched in the US. ... - Webbolt Business News (subscription),

AnorMED reports fiscal 2006 third quarter results and announces ... Feb 7, 2006
I safety study of MOZOBIL in cardiac patients - Receive milestone payments from Shire contingent upon additional European approvals for FOSRENOL - Select lead ... - MSN Money

End-stage renal disease: higher dose formulation of Fosrenol ... Dec 5, 2005
FDA ( US Food and Drug Administration ) has approved a new, higher dose formulation of the chewable non-calcium phosphate binder Fosrenol ( Lanthanum carbonate ... - Xagena.it,

New Higher Dose Formulation of FOSRENOL(R) Approved to Reduce ... Nov 28, 2005
The US Food and Drug Administration (FDA) has approved a new, higher dose formulation of the chewable(1) non-calcium phosphate binder FOSRENOL(R) (lanthanum ... - PR Newswire (press release),

New Higher Dose Formulation of FOSRENOL(R) Approved to Reduce ... Nov 28, 2005
Food and Drug Administration (FDA) has approved a new, higher dose formulation of the chewable(1) non-calcium phosphate binder FOSRENOL® (lanthanum carbonate ... - Yahoo! News (press release)

A Special Medical Radio News Report: New Formulation of FOSRENOL(R ... Nov 29, 2005
THE FDA HAS JUST APPROVED A NEW, HIGHER DOSE FORMULATION OF THE PHOSPHATE BINDER FOSRENOL® (FOSS-WREN-ALL) FOR END-STAGE RENAL DISEASE PATIENTS WHO HAVE ... - Yahoo! News (press release)

FDA approves higher dose of Fosrenol Nov 28, 2005
PHILADELPHIA, Nov. 28 (UPI) -- Shire said Monday the Food and Drug Administration has OK'd higher-dose Fosrenol to treat end-stage renal disease. ... - United Press International

Higher dose Fosrenol gets FDA approval Nov 28, 2005
The US Food and Drug Administration has reportedly approved a new formulation of the drug Fosrenol, used to treat end-stage renal disease. ... - Webindia123,

Shire Pharma Fosrenol Approval As Expected Nov 29, 2005
1306 GMT [Dow Jones] Shire Pharmaceutical's (SHPGY) approval from the FDA for a higher dose formulation of Fosrenol, "is entirely as expected," says trader. ... - New Ratings

New Six-year Data Supports FOSRENOL(R) as a Treatment Choice for ... Nov 12, 2005
Data Shows FOSRENOL(R) Works Long Term to Lower Phosphate Levels Effectively, and Further Reinforces its Safety and Tolerability Profile BASINGSTOKE, England ... - PR Newswire (press release),

NEW SIX-YEAR DATA SUPPORTS FOSRENOL(R) AS A TREATMENT CHOICE FOR ... Nov 12, 2005
According to data presented on Saturday at the annual meeting of the American Society of Nephrology (ASN), non-calcium FOSRENOL(R) (lanthanum carbonate ... - ITNews,

FOSRENOL(R) Demonstrates Long-Term Safety and Efficacy in End ... Nov 12, 2005
...- Additional Data Reveal That the FOSRENOL(R)-Phosphate Complex, in Vitro, May Be More Stable Than That of Sevelamer Hydrochloride in the Presence of Bile Acid ... - PR Newswire (press release),

Fosrenol Has Long-Term Safety and Efficacy in End-Stage Renal ... Nov 14, 2005
2005 -- According to data presented this weekend at the annual meeting of the American Society of Nephrology (ASN), non-calcium Fosrenol® (lanthanum carbonate ... - DG News

New six-year data supports Fosrenol® as a treatment choice for ... Nov 14, 2005
2005 - According to data presented on Saturday at the annual meeting of the American Society of Nephrology (ASN), non-calcium FOSRENOL® (lanthanum carbonate ... - Biotech Intelligence (press release),

Shire's Fosrenol News A Small Positive - ING Nov 13, 2005
0742 GMT [Dow Jones] Shire Pharmaceuticals (SHP.LN) says six-year study shows that its Fosrenol drug helps to lower phosphate levels in patients. ... - New Ratings

FOSRENOL(R) Demonstrates Long-Term Safety and Efficacy in End ... Nov 13, 2005
PRNewswire/ -- According to data presented this weekend at the annual meeting of the American Society of Nephrology (ASN), non-calcium FOSRENOL(R) (lanthanum ... - PR Newswire (press release),

Shire kidney drug shown to be effective over six years Nov 14, 2005
A long-term study has shown that Shire's non-calcium Fosrenol treatment effectively controls end-stage renal disease for up to six years, while also ... - Pharmaceutical Business Review

Snap: Shire kidney drug supported by study Nov 14, 2005
LONDON (SHARECAST) - Drug firm Shire Pharmaceuticals said that its severe kidney disease medicine Fosrenol was supported by a new six-year study. ... - ShareCast,

(PRN) - United Business Media Announces US$ 20.0m Convertible ... Nov 28, 2005
...(PRN) - New Higher Dose Formulation of FOSRENOL(R) Approved to Reduce Serum Phosphorus In End-Stage Renal Disease Patients ... [+. ... - Bolsamania.com,

Lenore Greenstein: Helping families cope with kidney disease Nov 28, 2005
For those who prefer a broader cuisine, a free cookbook called "Kidney Friendly Comfort Foods" can be ordered online — at www.fosrenol.com or 1-866-896-6152. ... - Naples Daily News (subscription),

London midmorning: Stocks push higher Nov 14, 2005
Shire Pharmaceuticals was also in focus after the group said new data on Fosrenol, its treatment for renal disease, demonstrated safety and effectiveness in ... - ShareCast,

AnorMED reports fiscal 2006 second quarter results, and progress ... Nov 8, 2005
10th-13th, 2005 - Report preliminary efficacy of AMD070 in HIV patients - Contingent upon additional European approvals for FOSRENOL, receive milestone ... - PR Newswire (press release),

FOSRENOL™ Renal Bone Disease Study Results Oct 3, 2005
Oviedo, Spain – Shire Pharmaceuticals Group plc (LSE:SHP.L, NASDAQ: SHPGY, TSE: SHQ CN) announces that FOSRENOL™ (lanthanum carbonate), its new phosphate ... - Biotechnology Investment Today (Press Release),

Genzyme "outperform" Sep 27, 2005
Physicians seem to favour Fosrenol and Genzyme would need to put in a lot of effort to explain the Medicare Part-D plan to physicians and successfully position ... - New Ratings

Some Shire Prescriptions Declining-Evolution Sep 30, 2005
0912 GMT [Dow Jones] Evolution notes some of Shire Pharmaceuticals' (SHPGY) drug prescriptions, including Fosrenol, have been showing some decline. ... - New Ratings

Nabi sues Ohio company over dialysis drug Sep 27, 2005
45 percent of the market. Newcomer Fosrenol from Shire Pharmaceuticals Group holds 8 percent to 10 percent, Nabi officials said. - Palm Beach Post,

Human resources Aug 17, 2005
Michael Ward has been recognized as one of the top sales representatives for Fosrenol by Shire Pharmaceuticals Group, which awarded him an upgraded lease on a ... - Birmingham News,